创伤患者全血复苏是否增加静脉血栓栓塞风险?3468例患者全血与成分治疗的比较
该研究纳入2016至2021年两家一级创伤中心3468例年龄≥18岁、接受至少1单位紧急放行血制品的创伤患者,比较复苏中使用全血(WB组1775例)与仅用成分治疗(COMP组1693例)的VTE(深静脉血栓和/或肺栓塞)发生率。WB组VTE发生率6% vs COMP组10%(P<0.001);WB组男性比例更高(82% vs 68%)、接受氨甲环酸比例更高(21% vs 16%)、损伤严重度评分更高(26 vs 19)(均P<0.001);WB组无住院天数(11 vs 15)、无ICU天数(23 vs 25)和30天生存率(74% vs 84)均更低(均P<0.001)。逻辑回归显示全血对VTE具有保护作用(OR 0.70,95%CI 0.54-0.91,P=0.009),而红细胞输注和氨甲环酸暴露增加VTE风险。作者认为需要进一步研究在早期具备全血输注能力时经验性使用氨甲环酸的VTE风险。
要点
- 在两家一级创伤中心3468例紧急输血创伤患者中,复苏使用全血与VTE风险降低相关(OR 0.70,95%CI 0.54-0.91,P=0.009)。
- 全血组VTE发生率6% vs 成分治疗组10%(P<0.001),但全血组损伤严重度评分更高(26 vs 19,P<0.001)。
- 红细胞输注和氨甲环酸暴露与VTE风险增加相关;全血组接受氨甲环酸比例21% vs 成分治疗组16%(P<0.001)。
- 全血组30天生存率74% vs 成分治疗组84%、无住院天数11 vs 15、无ICU天数23 vs 25(均P<0.001)。
- 作者认为需进一步研究在早期具备全血输注能力时经验性使用氨甲环酸的VTE风险。
适用人群与场景
- 2016至2021年两家一级创伤中心收治的年龄18岁及以上、接受至少1单位紧急放行血制品的创伤患者。
- 复苏期间接受任何全血的患者(WB组,1775例)与仅接受成分治疗的患者(COMP组,1693例)进行比较。
研究设计与关键结果
- 研究类型:在两家一级创伤中心开展的比较性研究,纳入3468例创伤患者(WB组1775例,COMP组1693例)。
- 主要终点VTE(深静脉血栓和/或肺栓塞)发生率:WB组6% vs COMP组10%(P<0.001)。
- WB组男性比例82% vs COMP组68%,接受氨甲环酸比例21% vs 16%,损伤严重度评分26 vs 19(均P<0.001)。
- WB组无住院天数11 vs COMP组15,无ICU天数23 vs COMP组25,30天生存率74% vs COMP组84%(均P<0.001)。
- 逻辑回归:全血对VTE具有保护作用(OR 0.70,95%CI 0.54-0.91,P=0.009);红细胞输注和氨甲环酸暴露增加VTE风险。
证据类型、等级与局限
- 证据类型:在两家一级创伤中心开展的比较性研究。
- 作者指出需要进一步研究,以评估在早期具备全血输注能力时经验性使用氨甲环酸的VTE风险。
对床旁实践的改变
- 作者认为:使用全血作为复苏的一部分与VTE风险降低30%相关,而氨甲环酸和红细胞输注增加VTE风险。
- 作者认为:需进一步研究在早期具备全血输注能力时经验性使用氨甲环酸的VTE风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Whole blood (WB) resuscitation has been shown to provide mortality benefit. However, the impact of whole blood transfusions on the risk of venous thromboembolism (VTE) remains unclear. We sought to compare the VTE risk in patients resuscitated with WB versus component therapy (COMP). Methods: Trauma patients aged 18 and older, admitted to two Level 1 trauma centers between 2016 and 2021, who received at least one unit of emergency-release blood products were identified. Clinical and transfusion data were collected. Patients that received any WB during resuscitation were compared to those who received only COMP therapy. The primary outcome was VTE incidence, defined as deep vein thrombosis and/or pulmonary embolism. Results: 3,468 patients met inclusion criteria (WB: 1,775, COMP: 1,693). WB patients were more likely to be male (82 vs. 68%), receive tranexamic acid (21 vs. 16%), and had higher Injury Severity Score (26 vs. 19; all P < 0.001). WB patients exhibited less hospital-free days (11 vs. 15), intensive care unit-free days (23 vs. 25), and 30-day survival (74 vs. 84; all P < 0.001). The WB group had lower VTE incidence (6 vs. 10%, P < 0.001). Logistic regression revealed WB was protective against VTE (OR 0.70, 95% CI 0.54-091, P = 0.009), while red blood cell transfusions and tranexamic acid (TXA) exposure increased VTE risk. Discussion: Using WB as part of resuscitation was associated with a 30% reduction in VTE, while TXA and red blood cell transfusion increased VTE risk. Further research is needed to evaluate VTE risk with empiric use of TXA in the setting of early WB transfusion capability.
参考来源
- Hout B, Van Gent JM, Clements T, et al. DOES WHOLE BLOOD RESUSCITATION INCREASE RISK FOR VENOUS THROMBOEMBOLISM IN TRAUMA PATIENTS? A COMPARISON OF WHOLE BLOOD VERSUS COMPONENT THERAPY IN 3,468 PATIENTS. Shock. 2024. PMID: 39617420. doi:10.1097/SHK.0000000000002508
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。